Aprea Therapeutics公司近日公布了其Wee1抑制剂候选药物Apr-1051在正在进行的I期ACESOT-1051临床试验中展现出的积极初步临床活性。试验数据显示,该药物已在一名患者中观察到经确认的部分缓解,这标志着该药物研发的一个重要里程碑。
Aprea Therapeutics公司近日公布了其Wee1抑制剂候选药物Apr-1051在正在进行的I期ACESOT-1051临床试验中展现出的积极初步临床活性。试验数据显示,该药物已在一名患者中观察到经确认的部分缓解,这标志着该药物研发的一个重要里程碑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.